--- title: "GR LIFE STYLE completes acquisition of Chunyu Doctor: holds 78% equity, founder Zhang Rui passed away ten years ago" type: "News" locale: "en" url: "https://longbridge.com/en/news/278827284.md" description: "GR LIFE STYLE has completed the strategic acquisition of Chunyu Doctor, holding approximately 78.3% of its equity. The transaction amount is 269 million yuan, and GR LIFE STYLE will complete the acquisition through the issuance of shares and cash payment. Chunyu Doctor's founder, Zhang Rui, passed away ten years ago. Chunyu Doctor was once a benchmark enterprise in the mobile medical field but missed several development opportunities after management adjustments" datetime: "2026-03-12T06:05:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278827284.md) - [en](https://longbridge.com/en/news/278827284.md) - [zh-HK](https://longbridge.com/zh-HK/news/278827284.md) --- # GR LIFE STYLE completes acquisition of Chunyu Doctor: holds 78% equity, founder Zhang Rui passed away ten years ago Leidi Network, March 12 Hong Kong-listed property management service company GR LIFE (00108.HK) announced yesterday the completion of its strategic acquisition of Chunyu Doctor, a benchmark enterprise in the domestic mobile medical field. After the completion of this transaction, GR LIFE will hold approximately 78.3% of Chunyu Doctor's equity. Following the completion of this strategic acquisition, GR LIFE stated that it will implement a strategy of independent operation and empowered development for Chunyu Doctor, retaining its core team and brand advantages while investing quality resources to assist in its further upgrade and development. It was reported that in December 2025, GR LIFE announced the acquisition of Chunyu Doctor for 269 million yuan (approximately 295 million HKD). GR LIFE will pay for the acquisition by issuing and distributing 147,393,029 shares at an issue price of 1.6 HKD per share. GR LIFE will make an initial cash payment of 20%, amounting to 53.8 million yuan (approximately 59 million HKD); the second cash payment will be 18.8 million HKD, in addition to a share payment of 217 million HKD. Chunyu Doctor's founder, Zhang Rui, has passed away for ten years. Chunyu Doctor is a regrettable case in the mobile internet industry. The founder, Zhang Rui, had several notable roles before founding "Chunyu Doctor": Director of the News Center at Jinghua Times, Deputy Editor-in-Chief at NetEase, and Founder of the NetEase News App. Chunyu Doctor was once very popular, but unfortunately, in October 2016, Zhang Rui passed away from a myocardial infarction. In August 2019, Chunyu Doctor's management was adjusted, with Zhang Rui's widow, Wang Yuxiao, appointed as CEO, Wang Jianguo as COO, and Chunyu Doctor's co-founder and former CEO, Zeng Baiyi, as CTO. After this, Chunyu Doctor missed several development windows. Those familiar with Zhang Rui lament that nearly ten years have passed since his death, and if he were still alive, Chunyu Doctor could very likely be a publicly listed company with a market value of 100 billion. BlueRun and Sogou are shareholders of Chunyu Doctor. Before this transaction, Wang Yuxiao held 9.77% of the shares, Zhang Jialin held 4.79%, Li Guanghui held 4.88%, Zeng Baiyi held 6.4%, Zhejiang Rushan Emerging Venture Capital Co., Ltd. held 1.88%, Zhejiang Rushan High-tech Venture Capital Co., Ltd. held 1.25%, and Tianjin Xinbaihao Enterprise Management Partnership (Limited Partnership) held 5.07%; Shanghai Dongzheng Chunyi Investment Center (Limited Partnership) held 13.99%, Mengbaihe Home Technology Co., Ltd. held 6.8%, Jiaxing BlueRun Yuchuan Enterprise Management Partnership (Limited Partnership) held 14.23%, Beijing Sogou Information Service Co., Ltd. held 5.19%, and Tianjin BlueRun Xinhai Investment Center (Limited Partnership) held 1.04% The announcement shows that Beijing Chunyu Tianxia Software Co., Ltd. has revenues of 101 million yuan and 66.23 million yuan for 2023 and 2024, respectively; net losses after tax are 9.57 million yuan and 22.95 million yuan, respectively; for the first 10 months of 2025, revenues are 51.05 million yuan, and the net loss after tax is 2.92 million yuan. ——————————————— ### Related Stocks - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [516610.CN](https://longbridge.com/en/quote/516610.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [00108.HK](https://longbridge.com/en/quote/00108.HK.md) ## Related News & Research - [GR Life Style Shareholders Unanimously Approve Consideration Share Issuance at EGM](https://longbridge.com/en/news/285958711.md) - [Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches](https://longbridge.com/en/news/285564515.md) - [Fine Foods announces availability of interim management report for Q1 2026](https://longbridge.com/en/news/286103409.md) - [MERCK: SIGNS MOU WITH TWO CHINESE COMPANIES TO ADVANCE CLINICAL COOPERATION - STATEMENT](https://longbridge.com/en/news/286065522.md) - [CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge](https://longbridge.com/en/news/285858047.md)